Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern, including Omicron variant
Authors:
- Irina A. FavorskayaIFIrina A. Favorskaya
- Dmitry V. ShcheblyakovDSDmitry V. Shcheblyakov
- Ilias B. EsmagambetovIEIlias B. Esmagambetov
- Inna V. DolzhikovaIDInna V. Dolzhikova
- Irina A. AlekseevaIAIrina A. Alekseeva
- Anastasia I. KorobkovaAKAnastasia I. Korobkova
- Daria V. VoroninaDVDaria V. Voronina
- Ekaterina I. RyabovaEREkaterina I. Ryabova
- Artem A. DerkaevADArtem A. Derkaev
- Anna V. KovyrshinaAKAnna V. Kovyrshina
- Anna A. IliukhinaAIAnna A. Iliukhina
Preprint
Abstract
Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibodies with a broad spectrum of neutralizing activity is urgently needed. Here we isolated a panel of single-domain antibodies that specifically bind to the receptor-binding domain of SARS-CoV-2 S glycoprotein. Three of the selected antibodies exhibiting most robust neutralization potency were used to generate dimeric molecules. We observed that these modifications resulted in up to a 200-fold increase in neutralizing activity. The most potent heterodimeric molecule efficiently neutralized each of SARS-CoV-2 variant of concern, including Alpha, Beta, Gamma, Delta and Omicron variants. This heterodimeric molecule could be a promising drug candidate for a treatment for COVID-19 caused by virus variants of concern.Keywords
This publication has 45 references indexed in Scilit:
- Molecular analysis of heavy chain-only antibodies of Camelus bactrianusBiochemistry (Moscow), 2014
- Nanobodies: Natural Single-Domain AntibodiesAnnual Review of Biochemistry, 2013
- Single-domain antibodies as building blocks for novel therapeuticsCurrent Opinion in Pharmacology, 2008
- Approximate Likelihood-Ratio Test for Branches: A Fast, Accurate, and Powerful AlternativeSystematic Biology, 2006
- Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritisArthritis & Rheumatism, 2006
- Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodiesProceedings of the National Academy of Sciences, 2006
- MUSCLE: multiple sequence alignment with high accuracy and high throughputNucleic Acids Research, 2004
- A Simple, Fast, and Accurate Algorithm to Estimate Large Phylogenies by Maximum LikelihoodSystematic Biology, 2003
- Antifungal activity of Artemisia annua endophyte cultures against phytopathogenic fungiJournal of Biotechnology, 2001
- Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chainsNucleic Acids Research, 1991